Inhibition of glutamine uptake by SLC1A5/ASCT2 inhibitor V-9302 additionally induces a marked reduction of tumor growth in vivo, which is accompanied by enhanced activation and functionality of effector T cells (Figure 4B). Here, SLC1A5 is linked to neoplasm.